APC-targeted immunization for the treatment of HIV-1

  title={APC-targeted immunization for the treatment of HIV-1},
  author={Franco Lori and Laurene M. Kelly and Julianna Lisziewicz},
  journal={Expert Review of Vaccines},
  pages={S189 - S198}
Therapeutic immunization may be thought of as an adjunct to highly active antiretroviral therapy to prime the immune system and possibly correct for immunological defects. Most therapeutic vaccine strategies currently under investigation aim to increase HIV-specific cellular responses. This may be most successfully accomplished by utilizing professional antigen-presenting cells. Autologous dendritic cells may be isolated, cultured, loaded with antigen and re-injected into the subject (ex vivo… Expand

Paper Mentions

Observational Clinical Trial
PHPC-02 is a phase II, randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces… Expand
ConditionsHIV Infection
InterventionBiological, Drug
Dendritic cell‐based human immunodeficiency virus vaccine
  • C. Rinaldo
  • Medicine
  • Journal of internal medicine
  • 2009
Dendritic cells (DC) have profound abilities to induce and coordinate T‐cell immunity. This makes them ideal biological agents for use in immunotherapeutic strategies to augment T‐cell immunity toExpand
Divergence in CD8+ T cell epitopes of HIV -1 as an immune escape mechanism
Initial data is provided that support that CD8⁺ T cells can be primed by in vitro engineered DC, even against autologous HIV-1 peptides representing immune escape variants, and it is demonstrated that the use of autOLOGous viral sequences expands both memory and primary T cell responses in vitro. Expand
The potential of topical DNA vaccines adjuvanted by cytokines
This review focuses on the action of several cytokines tested as molecular adjuvants for DNA vaccines and the combination of them with the DermaVir Patch vaccine. Expand
Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field
There is growing hope that combination vaccine strategies that can induce broader and longer-lived systemic and mucosal immunity will yield an HIV-1 vaccine with improved efficacy. Expand
Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation.
The gene delivery effectiveness provided by mannosylated PBAE vectors offers specificity and potency in directing APC activation and subsequent immune responses and is presented as a new class of easily synthesized APC-targeting cationic polymers. Expand
Comparative analysis of macrophage associated vectors for use in genetic vaccine
Macroialin promoter can be utilized for targeting macrophage dominant expression in genetic vaccines and in vivo study needs to be carried out for its utility as a vaccine candidate. Expand
Dendritic Cell Function during Chronic Hepatitis C Virus and Human Immunodeficiency Virus Type 1 Infection
It is shown that monocyte-derived DCs from persons with chronic HCV infection, with or without HIV-1 coinfection, being treated with combination antiretroviral therapy produced lower levels of interleukin 12 p70 in response to CD40 ligand, whereas the expression of DC surface activation and costimulatory molecules was unimpaired. Expand
Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promoters
The APC-expressing DNA vaccination approach induces comparable immunity in comparison to ubiquitous promoter construct, and the predominant Th1 type immune responses provide opportunities to further test its potency suitable for response in antiviral or anticancer vaccines. Expand
HIV Vaccines in Infants and Children
The results of a number of HIV vaccine trials performed in HIV-exposed and -infected children were encouraging, but the immunogenicity was poor and future planned vaccine studies are focused on prime-boost approaches, using live recombinant vectors or DNA vaccines combined with subunit vaccines to stimulate both cellular and antibody responses. Expand


Strategies for designing vaccines eliciting Th1 responses in humans.
  • P. Moingeon
  • Biology, Medicine
  • Journal of biotechnology
  • 2002
Emerging technologies and a better understanding of the physiology of immune responses offer new avenues to rationally design such vaccines, including Th1 adjuvants, which would be useful in redirecting inappropriate antigen-specific immune responses in patients with autoimmune diseases and allergies. Expand
New gene-based approaches for an AIDS vaccine.
  • A. Puaux, M. Michel
  • Biology, Medicine
  • Comparative immunology, microbiology and infectious diseases
  • 2003
Results suggest that priming with DNA and boosting with attenuated recombinant viral vectors, each expressing corresponding SIV antigens, leads to improved specific immunity and, in some cases, affords protection against pathogenic challenge. Expand
Therapeutic dendritic-cell vaccine for simian AIDS
Molecular and cellular analyses of axillary and inguinal node lymphocytes of vaccinated monkeys revealed a correlation between decreased SIV DNA and RNA levels and increased SIV-specific T-cell responses, and inactivated whole virus-pulsed dendritic cell vaccines are promising means to control diseases caused by immuno- deficiency viruses. Expand
Immunization with DNA through the skin.
Dermal immunization methods described in this article target the epidermis, the dermis, or both and include the removal of hair, the circumvention or modification of the stratum corneum layer of the epidersmis, and the addition of DNA or amplification of DNA signal. Expand
Antigen presentation and the role of dendritic cells in HIV
Current vaccine initiatives involving pulsing dendritic cells with virus proteins, infected apototic or whole inactivated virions is proving a useful tool in the induction, expansion and maintenance of antiviral cell-mediated immunity. Expand
In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen.
The power of DNA delivery in vivo for both the production of a new generation of more effective and targeted vaccines or immunotherapies as well as an analytic tool for the molecular dissection of the mechanisms of immune function is demonstrated. Expand
Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
This work has developed expression cassettes for cell surface markers CD80 and CD86, two functionally related costimulatory molecules that play an important role in the induction of T cell-mediated immune responses and observed a dramatic increase in cytotoxic T-lymphocyte induction as well as T-helper cell proliferation after the coadministration of CD86 genes. Expand
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
The protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys is reported, with no evidence of clinical disease or mortality after challenge. Expand
Therapeutic vaccination for future management of HIV/AIDS.
A novel immunotherapeutic agent that delivers plasmid DNA to dendritic cells after topical skin application is the first therapeutic vaccine that has demonstrated immunological and clinical benefit in chronically infected rhesus macaques in combination with antiretroviral therapy. Expand
Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells
A novel technology combining replication- and integration-defective human immunodeficiency virus type 1 (HIV-1) vectors with genetically modified dendritic cells was developed in order to induce T-cell immunity, circumventing the problem of obtaining viral vector expression in the absence of integration. Expand